Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Authors
Keywords
Melanoma, Ipilimumab, CTLA4, Neoadjuvant, Cytokines
Journal
Journal for ImmunoTherapy of Cancer
Volume 3, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-08-27
DOI
10.1186/s40425-015-0081-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma
- (2014) Ahmad A Tarhini et al. Journal of Translational Medicine
- Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa
- (2014) Ahmad A. Tarhini et al. MELANOMA RESEARCH
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma
- (2014) Faruk Tas et al. TUMOR BIOLOGY
- High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer
- (2014) Rumeysa Ciftci et al. TUMOR BIOLOGY
- Plasma Cytokine Analysis in Patients with Advanced Extremity Melanoma Undergoing Isolated Limb Infusion
- (2013) Gina Shetty et al. ANNALS OF SURGICAL ONCOLOGY
- Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
- (2012) Ahmad A. Tarhini et al. JOURNAL OF IMMUNOTHERAPY
- Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma
- (2011) Gregory K. Pennock et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- An update on transforming growth factor-β (TGF-β): Sources, types, functions and clinical applicability for cartilage/bone healing
- (2011) A. S. Patil et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Multiplex serum biomarker assessments: technical and biostatistical issues
- (2011) Lisa H Butterfield et al. Journal of Translational Medicine
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-23/Th17 pathways and inflammatory bowel disease
- (2009) Clara Abraham et al. INFLAMMATORY BOWEL DISEASES
- Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
- (2009) Marianna Sabatino et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started